
In the PACMAN-AMI trial, investigating high-intensity lipid-lowering therapy effects, 31.7% of acute myocardial infarction patients showed triple regression (atheroma volume, lipid content, fibrous cap). Alirocumab treatment, higher baseline lipid content, and triple regression were linked. Triple regression associates with reduced cardiovascular events, highlighting its potential as a therapeutic target.
Like
Save
Share